Biorestorative Therapies, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $300,000, 83% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Mar 31, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Product |
—
|
0
+0.0%
share 83.4%
|
0
share 74.8%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Royalty |
—
|
0
-40.9%
share 16.6%
|
0
-30.7%
share 25.2%
|
0
share 100.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Misc Health & Allied Services, NEC (SIC 8090)
- Listed as
- BRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Melville, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1505497
- Former names
- Stem Cell Assurance, Inc. (until Aug 16, 2011)
Other Services-Misc Health & Allied Services, NEC companies
- Fresenius Medical Care AG FMS
- Davita Inc. DVA
- Sotera Health Co SHC
- Progyny, Inc. PGNY
- agilon health, inc. AGL
- Charming Medical Ltd MCTA
- Viemed Healthcare, Inc. VMD
- Park Dental Partners, Inc. PARK
All 15 Services-Misc Health & Allied Services, NEC companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.